Literature DB >> 10593481

In vivo adaptation of SHIV(SF162): chimeric virus expressing a NSI, CCR5-specific envelope protein.

R C Tan1, J M Harouse, A Gettie, C Cheng-Mayer.   

Abstract

The chemokine receptor CCR5 is known to be a critical determinant of human immunodeficiency virus (HIV) transmission and pathogenesis in the human host. Towards the development of a macaque model to evaluate the efficacy of vaccines and therapeutics against infection with CCR5-specific viruses, and to delineate the pathogenic properties of such viruses, we constructed a chimeric simian human immunodeficiency virus, SHIV(SF162), containing the env, tat, rev, and vpu genes from HIV-1(SF162) (R5, MT/NSI) in the context of the molecular clone simian immunodeficiency virus, SIV(mac239). Virus generated from this molecular clone was used to intravenously infect two juvenile macaques, followed by three consecutive serial blood/bone marrow transfusions. Animals infected with parental SHIV(SF162) (P1) had detectable levels of viral replication (as determined by p27(gag) production) within days of infection; however, viral set-points fell below detection by Week 3. Late passage animals (P3 and P4) had a two-log increase in the level of plasma p27(gag) antigen. These results demonstrate that in vivo serial passage of the R5-specific SHIV(SF162) enhanced its replicative capacity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10593481     DOI: 10.1111/j.1600-0684.1999.tb00265.x

Source DB:  PubMed          Journal:  J Med Primatol        ISSN: 0047-2565            Impact factor:   0.667


  39 in total

1.  Ex vivo analysis of SIV-infected cells by flow cytometry.

Authors:  Matthew R Reynolds; Shari M Piaskowski; Kimberly L Weisgrau; Andrea M Weiler; Thomas C Friedrich; Eva G Rakasz
Journal:  Cytometry A       Date:  2010-11       Impact factor: 4.355

2.  Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis.

Authors:  Nagadenahalli B Siddappa; Girish Hemashettar; Yin Ling Wong; Samir Lakhashe; Robert A Rasmussen; Jennifer D Watkins; Francis J Novembre; François Villinger; James G Else; David C Montefiori; Ruth M Ruprecht
Journal:  J Med Primatol       Date:  2010-11-02       Impact factor: 0.667

3.  Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.

Authors:  Dennis R Burton; Ann J Hessell; Brandon F Keele; Per Johan Klasse; Thomas A Ketas; Brian Moldt; D Cameron Dunlop; Pascal Poignard; Lara A Doyle; Lisa Cavacini; Ronald S Veazey; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-20       Impact factor: 11.205

4.  Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3).

Authors:  J M Harouse; A Gettie; T Eshetu; R C Tan; R Bohm; J Blanchard; G Baskin; C Cheng-Mayer
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

5.  Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.

Authors:  Timothy R Fouts; Kenneth Bagley; Ilia J Prado; Kathryn L Bobb; Jennifer A Schwartz; Rong Xu; Robert J Zagursky; Michael A Egan; John H Eldridge; Celia C LaBranche; David C Montefiori; Hélène Le Buanec; Daniel Zagury; Ranajit Pal; George N Pavlakis; Barbara K Felber; Genoveffa Franchini; Shari Gordon; Monica Vaccari; George K Lewis; Anthony L DeVico; Robert C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-13       Impact factor: 11.205

6.  Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques.

Authors:  J Pablo Jaworski; James Kobie; Zachary Brower; Delphine C Malherbe; Gary Landucci; William F Sutton; Biwei Guo; Jason S Reed; Enrique J Leon; Flora Engelmann; Bo Zheng; Al Legasse; Byung Park; Mary Dickerson; Anne D Lewis; Lois M A Colgin; Michael Axthelm; Ilhem Messaoudi; Jonah B Sacha; Dennis R Burton; Donald N Forthal; Ann J Hessell; Nancy L Haigwood
Journal:  J Virol       Date:  2013-07-24       Impact factor: 5.103

7.  Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus.

Authors:  Christopher Sundling; Sijy O'Dell; Iyadh Douagi; Mattias N Forsell; Andreas Mörner; Karin Loré; John R Mascola; Richard T Wyatt; Gunilla B Karlsson Hedestam
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

8.  Nonpathogenic CCR2-tropic SIVrcm after serial passage and its effect on SIVmac infection of Indian rhesus macaques.

Authors:  Binhua Ling; Ronald S Veazey; Preston A Marx
Journal:  Virology       Date:  2008-07-26       Impact factor: 3.616

9.  R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models.

Authors:  Nagadenahalli B Siddappa; Jennifer D Watkins; Klemens J Wassermann; Ruijiang Song; Wendy Wang; Victor G Kramer; Samir Lakhashe; Michael Santosuosso; Mark C Poznansky; Francis J Novembre; François Villinger; James G Else; David C Montefiori; Robert A Rasmussen; Ruth M Ruprecht
Journal:  PLoS One       Date:  2010-07-21       Impact factor: 3.240

10.  Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.

Authors:  Ann J Hessell; Eva G Rakasz; Pascal Poignard; Lars Hangartner; Gary Landucci; Donald N Forthal; Wayne C Koff; David I Watkins; Dennis R Burton
Journal:  PLoS Pathog       Date:  2009-05-15       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.